Sirio Pharma Cash Flow Quality Index
Sirio Pharma cash flow quality index. Sirio Pharma (300791) has a Cash Flow Quality Index of 1.42x as of June 2023. Operating cash flow of CN¥101.61 Million exceeds net income of CN¥71.79 Million, indicating high earnings quality where cash backs reported profits. Explore 300791 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Sirio Pharma (2016–2024)
Cash flow quality index of Sirio Pharma from 2016 to 2024. Historical Cash Flow Quality Index for Sirio Pharma across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. See how leveraged is Sirio Pharma's balance sheet to measure how much of total assets are equity-financed.
Sirio Pharma Cash Flow Quality Index by Year (2016–2024)
Sirio Pharma cash flow quality index by year from 2016 to 2024. Year-by-year earnings quality comparison for Sirio Pharma. For the full cash flow conversion analysis, see 300791 cash generation efficiency.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.74x | CN¥566.97 Million | CN¥325.06 Million | ▲ +27.0% |
| 2023 | 1.37x | CN¥386.08 Million | CN¥281.04 Million | ▼ -34.4% |
| 2022 | 2.10x | CN¥444.86 Million | CN¥212.29 Million | ▲ +42.3% |
| 2021 | 1.47x | CN¥341.38 Million | CN¥231.83 Million | ▲ +18.6% |
| 2020 | 1.24x | CN¥319.57 Million | CN¥257.37 Million | ▼ -23.6% |
| 2019 | 1.63x | CN¥231.60 Million | CN¥142.53 Million | ▲ +80.0% |
| 2018 | 0.90x | CN¥183.46 Million | CN¥203.23 Million | ▲ +90.8% |
| 2017 | 0.47x | CN¥49.35 Million | CN¥104.30 Million | ▲ +438.9% |
| 2016 | -0.14x | CN¥-98.26 Million | CN¥703.73 Million | — |